KB손보, Industry First to Obtain Exclusive Rights for 'Thyroid and Prostate Needle Biopsy Fees'

Expanding Insurance Coverage to the Pre-Diagnostic Stage?

[Asia Economy Reporter Oh Hyung-gil] KB Insurance announced on the 10th that it has obtained an exclusive usage right for three months from the General Insurance Association for the 'Thyroid and Prostate Needle Biopsy Tissue Pathology Diagnosis Fee,' which was first introduced in the industry in its cancer-specific product 'KB Cancer Insurance and the Story of Living Healthily,' launched last May.

The exclusive usage right obtained this time covers the Thyroid and Prostate Needle Biopsy Tissue Pathology Diagnosis Fee, which provides insurance benefits not only when cancer is confirmed through tissue pathology diagnosis via 'needle biopsy' for differential diagnosis of thyroid and prostate diseases but also once annually even if the result is not cancer. Thyroid and prostate needle biopsy generally refers to a test in which a thin needle is inserted into the body to obtain tissue samples when there are suspicious findings of disease in ultrasound or other radiological examinations, blood tests, or physical examinations of the thyroid and prostate. This new coverage guarantee development received high marks for originality and effort from a preventive perspective and was granted exclusive usage rights.

KB Insurance expanded its coverage area with a preventive cancer insurance that prevents progression to severe diseases through early diagnosis by providing coverage for 'benign tumors and polyps (adenomas) diagnosis fees of the stomach, duodenum, and colon,' which are pre-cancerous stages.

Meanwhile, the newly launched 'KB Cancer Insurance and the Story of Living Healthily' by KB Insurance last month is the industry's first product to cover the latest cancer treatment method, 'targeted anticancer drug approval treatment fee.' It is a new product that changes the coverage paradigm from cancer insurance focused on existing cancer treatment costs to cancer insurance for a healthy life after cancer treatment. Through these industry-first new coverages, it has attracted significant customer interest, achieving about 30,000 sales by the end of May since its launch on the 15th of last month.

Joon-sung Bae, Executive Director of the Long-term Product Headquarters at KB Insurance, said, "With the acquisition of this exclusive usage right, we have established a new paradigm for cancer insurance through insurance coverage from a disease prevention perspective," adding, "KB Insurance will continue to develop innovative products that can lead the market by reflecting various customer needs."

This content was produced with the assistance of AI translation services.